Tapinarof is primarily used in the treatment of plaque psoriasis, a chronic autoimmune skin condition characterized by red, scaly patches on the skin. It works by modulating the immune response and reducing inflammation, helping to alleviate symptoms and improve skin appearance. The compound is applied topically, making it a convenient option for patients seeking localized treatment without systemic side effects. Its mechanism of action involves targeting the aryl hydrocarbon receptor (AhR), which plays a role in skin barrier function and immune regulation. This targeted approach makes it effective in managing mild to moderate psoriasis, offering an alternative to traditional therapies like corticosteroids or phototherapy. Additionally, its non-steroidal nature reduces the risk of side effects associated with long-term steroid use, such as skin thinning. Tapinarof is particularly beneficial for patients who prefer a non-invasive treatment option or have not responded well to other therapies. Its development represents a significant advancement in dermatological care, providing a novel and effective solution for managing psoriasis.